Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal–bolus regimens: insights from the PREDICTIVE study

References

• Nathan DM, Buse JB, Davidson MB. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2008. Diabetes Care 2008;31(Suppl. 1):S12-S54
   PubMedGoogle Scholar
• Guideline for Management of Postmeal Glucose. Brussels: IDF, 2007. Available at: http://www.idf.org/webdata/docs/Guideline_PMG_final.pdf [Last accessed 23 December 2008]
   Google Scholar
• Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26(Suppl. 3):S18-24
   PubMedGoogle Scholar
• Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988;318(19):1231-9
   PubMed Web of Science ®Google Scholar
• Home PD, Lindholm A, Hylleberg B, et al. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 1998;21(11):1904-9
   PubMed Web of Science ®Google Scholar
• Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal–bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622-9
   PubMed Web of Science ®Google Scholar
• Rašlová K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: a promising basal–bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66(2):193-201. Corrigendum: Diabetes Res Clin Pract 2006;72:112
   Google Scholar
• Ashwell SG, Amiel SA, Bilous RW, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabet Med 2006;23(3):285-92
   PubMed Web of Science ®Google Scholar
• Murphy NP, Keane SM, Ong KK, et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003;26(3):799-804
   PubMed Web of Science ®Google Scholar
• Luddeke H-J, Sreenan S, Aczel S, et al. PREDICTIVE(TM): a global, perspective observational study to evaluate insulin detemir treatment in type 1 or type 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab 2007;9:428-34
   PubMed Web of Science ®Google Scholar
• Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal–bolus regimen with premeal insulin aspart. Diabetes Care 2003;26:590-6
   PubMed Web of Science ®Google Scholar
• Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes; a randomised clinical trial. Diabetes Care 2004;27:1081-7
   PubMed Web of Science ®Google Scholar
• Kølendorf K, Ross GP, Pavlic-Renar I, et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabet Med 2006;23:729-35
   PubMed Web of Science ®Google Scholar
• Dornhorst A, Luddeke H-J, Sreenan S, et al. on behalf of the PREDICTIVE study group. Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE™ study. Int J Clin Pract 2008;62(4):659-65
   Google Scholar
• Russell-Jones D, Simpson R, Hylleberg B, et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal–bolus regimen. Clin Ther 2004;26(5):724-36
   PubMed Web of Science ®Google Scholar
• Pieber TR, Draeger E, Kristensen A, et al. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005;22:850-7
   PubMed Web of Science ®Google Scholar
• Sreenan S, Virkamäki A, Zhang K, et al. Switching from NPH insulin to once-daily insulin detemir in basal–bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE™ study. IJCP 2008;62(12):1971-80
   Google Scholar
• Bartley PC, Bogoev M, Larsen J, et al. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008;25(4):442-9
   Google Scholar
• Dornhorst A, Lüddeke HJ, Honka M, et al. Safety and efficacy of insulin detemir basal–bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Curr Med Res Opin 2008;24(2):369-76
   Google Scholar
• Devries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues?. Diabetes Metab Res Rev 2007;23(6):441-54
   Google Scholar
• Home P, Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother 2006;7(3):325-43
   Google Scholar